Search

Displaying results 1601 - 1610 of 10000 in total
  1. Drug

    Piribedil

    go.drugbank.com/drugs/DB12478
    Investigational

    Piribedil has been investigated in Parkinson's Disease.

    Products: TRIVASTAL RETARD 50 TABLET 50 mg, TRIVASTAL 50 MG RETARD TABLET, 30 ADET
  2. Drug

    Metenolone

    go.drugbank.com/drugs/DB13710
    Investigational

    Products: RIMOBOLAN 100MG/1 ML ENJEKSIYONLUK COZELTI ICEREN AMPUL, 100 ADET, RIMOBOLAN 100MG/1 ML ENJEKSIYONLUK COZELTI ICEREN AMPUL, 50 ADET
  3. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830] … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: XOSPATA 40 MG FİLM KAPLI TABLET, 84 ADET
  4. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    It is available in topical formulations for the treatment of skin infections such as athlete's foot.

    Products: ZALAIN VAGINAL SUPPOSITORY 300 mg, GYNO-ZALAIN 300 MG OVULO VAGINAL
  5. Drug

    Josamycin

    go.drugbank.com/drugs/DB01321
    Investigational

    The drug has antimicrobial activity against a wide spectrum of pathogens.

    Products: Josalid 500 mg - Filmtabletten, Josalid 250 mg/5 ml - Saft für Kinder
  6. Drug

    Choriogonadotropin alfa

    go.drugbank.com/drugs/DB00097
    ApprovedInvestigational

    -13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). … Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN

    Products: Ovidrel Solution for Injection 250 mcg, OVITRELLE 250 MCG/0,5 ML KULLANIMA HAZIR ŞIRINGADA ENJEKSİYONLUK ÇÖZELTİ, 1 ADET
  7. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    Calcifediol also has mineralizing properties.

    Synonyms: (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diolMixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)
  8. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTAS
  9. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InducersProducts: ERLEADA ®TABLETAS RECUBIERTAS 60 MG
  10. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsProducts: XALKORI 200 MG KAPSUL, 60 ADET, XALKORI®250 MG CÁPSULAS